{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T15:01:06Z","timestamp":1775919666877,"version":"3.50.1"},"reference-count":42,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T00:00:00Z","timestamp":1728086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>In Thailand, an upper\u2010middle\u2010income country, managing haemophilia A (HA) with inhibitors poses significant challenges, often necessitating bypassing agents (BPAs) for bleeding control. This study evaluates the cost\u2010effectiveness and budget impact of emicizumab, a novel prophylactic agent, as an alternative to both episodic and prophylactic BPA treatments from a societal perspective.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A Markov model was employed to estimate the lifetime societal costs and outcomes of emicizumab prophylaxis for HA patients with inhibitors. Treatment efficacy, cost, and epidemiological data were obtained through a comprehensive literature review and incorporated into the model. A 5\u2010year budget impact analysis complemented the cost\u2010utility analysis, with a 3% annual discount rate applied to future costs and outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the base\u2010case scenario, emicizumab prophylaxis in HA patients aged 2 years and above demonstrated superior cost\u2010effectiveness, yielding 18.1 quality\u2010adjusted life years (QALYs) per patient over a lifetime and resulting in cost savings of 138 million Thai Baht (THB) compared to BPA prophylaxis. Compared to episodic BPA treatment, emicizumab yielded 30.5 QALYs and saved 25 million THB per patient. The 5\u2010year budget impact was projected at 1775 million THB.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Emicizumab offers a cost\u2010saving approach for HA treatment with inhibitors in Thailand, promising significant health benefits and budgetary savings. This supports its potential inclusion in Thailand's National List of Essential Medicines to enhance haemophilia care access.<\/jats:p><\/jats:sec><jats:sec><jats:title>Highlights<\/jats:title><jats:p><jats:list list-type=\"bullet\">\n<jats:list-item><jats:p>Managing haemophilia A (HA) with inhibitors in Thailand, an upper\u2010middle\u2010income country, faces challenges due to limited access to effective treatments or newer drugs for bleeding management.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Emicizumab prophylaxis found to as a cost\u2010effective and viable alternative to traditional treatments, effectively preventing bleeding in Thai HA patients over 2 years old with inhibitors.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Demonstrating improved clinical outcomes and reduced costs, emicizumab prophylaxis outperforms episodic BPA treatments, positioning it as a superior treatment option for HA patients with inhibitors in Thailand.<\/jats:p><\/jats:list-item>\n<\/jats:list><\/jats:p><\/jats:sec>","DOI":"10.1111\/hae.15105","type":"journal-article","created":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T15:34:17Z","timestamp":1728142457000},"page":"1288-1297","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluating the benefits of emicizumab prophylaxis for haemophilia A with inhibitors: A cost\u2010effectiveness and budget impact analysis in Thailand's upper\u2010middle income setting"],"prefix":"10.1111","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6726-5706","authenticated-orcid":false,"given":"Kirati","family":"Kengkla","sequence":"first","affiliation":[{"name":"Division of Clinical Pharmacy, Department of Pharmaceutical Care, School of Pharmaceutical Sciences University of Phayao  Mueang Phayao Phayao Thailand"},{"name":"Center of Health Outcomes Research and Therapeutic Safety (Cohorts), School of Pharmaceutical Sciences University of Phayao  Mueang Phayao Phayao Thailand"},{"name":"Unit of Excellence on Clinical Outcomes Research and IntegratioN (UNICORN), School of Pharmaceutical Sciences University of Phayao  Mueang Phayao Phayao Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4389-4476","authenticated-orcid":false,"given":"Preyanate","family":"Wilairat","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacy, Department of Pharmaceutical Care, School of Pharmaceutical Sciences University of Phayao  Mueang Phayao Phayao Thailand"},{"name":"Center of Health Outcomes Research and Therapeutic Safety (Cohorts), School of Pharmaceutical Sciences University of Phayao  Mueang Phayao Phayao Thailand"},{"name":"Unit of Excellence on Clinical Outcomes Research and IntegratioN (UNICORN), School of Pharmaceutical Sciences University of Phayao  Mueang Phayao Phayao Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9840-3443","authenticated-orcid":false,"given":"Rungrote","family":"Natesirinilkul","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Pediatrics, Faculty of Medicine Chiang Mai University  Chiangmai Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1097-3482","authenticated-orcid":false,"given":"Darintr","family":"Sosothikul","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Pediatrics, Faculty of Medicine Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok and Integrative and Innovative Hematology\/Oncology Research Unit, Faculty of Medicine  Chulalongkorn Bangkok Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1995-4405","authenticated-orcid":false,"given":"Pochamana","family":"Phisalprapa","sequence":"additional","affiliation":[{"name":"Division of Ambulatory Medicine, Department of Medicine Faculty of Medicine Siriraj Hospital, Mahidol University  Bangkok Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surasak","family":"Saokaew","sequence":"additional","affiliation":[{"name":"Center of Health Outcomes Research and Therapeutic Safety (Cohorts), School of Pharmaceutical Sciences University of Phayao  Mueang Phayao Phayao Thailand"},{"name":"Unit of Excellence on Clinical Outcomes Research and IntegratioN (UNICORN), School of Pharmaceutical Sciences University of Phayao  Mueang Phayao Phayao Thailand"},{"name":"Division of Social and Administrative Pharmacy (SAP), Department of Pharmaceutical Care School of Pharmaceutical Sciences, University of Phayao  Mueang Phayao Phayao Thailand"},{"name":"Center of Excellence in Bioactive Resources for Innovative Clinical Applications Chulalongkorn University  Bangkok Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,10,5]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14046"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14270"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.7326\/M19-1208"},{"issue":"6","key":"e_1_2_11_5_1","first-page":"479","article-title":"Factor VIII replacement is still the standard of care in haemophilia A","volume":"17","author":"Aledort L","year":"2019","journal-title":"Blood Transfus"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01919-w"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.5045\/br.2019.54.3.204"},{"key":"e_1_2_11_8_1","first-page":"106","article-title":"Hemophilia with factor VIII and factor IX inhibitors, incidence, bleeding problems and management","volume":"24","author":"Mahasandana C","year":"1993","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005456"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14456"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057479"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2942"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803550"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703068"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001869"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-3401822"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14143"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14129"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27014"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14723"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14524"},{"key":"e_1_2_11_22_1","first-page":"S4","article-title":"Guidelines for health technology assessment in Thailand (second edition)\u2013the development process","volume":"97","author":"Chaikledkaew U","year":"2014","journal-title":"J Med Assoc Thai"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1538-7836.2004.00710.x"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.01808.x"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.02188.x"},{"key":"e_1_2_11_26_1","volume-title":"National list of essential medicine: reference price","year":"2022"},{"key":"e_1_2_11_27_1","unstructured":"Drug and medical supply information center. National list of essential medicine: reference price.2022;http:\/\/dmsic.moph.go.th\/index"},{"key":"e_1_2_11_28_1","unstructured":"Health Intervention and Technology Assessment Program (HITAP). Standard Cost List for Health Technology Assessment."},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13618"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2014.02.008"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-872291"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14005"},{"issue":"3","key":"e_1_2_11_33_1","first-page":"223","article-title":"Emicizumab for the treatment of haemophilia A: a narrative review","volume":"17","author":"Franchini M","year":"2019","journal-title":"Blood Transfus"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100852"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2012.02909.x"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S175952"},{"key":"e_1_2_11_37_1","unstructured":"World Federation of Hemophilia.Annual global survey2020;https:\/\/www1.wfh.org\/publications\/files\/pdf\u20102045.pdf"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14194"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2013.08.019"},{"issue":"3","key":"e_1_2_11_40_1","article-title":"Comparison between hospital care costs with reimbursement on diagnosis related group (DRG) payment systemand outcomes of therapeutic plasma exchange (TPE) at Naresuan university hospital","volume":"48","author":"Sirilak S","year":"2018","journal-title":"J. Public Health"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079908X273048"},{"issue":"3","key":"e_1_2_11_42_1","first-page":"183","article-title":"Comparison of direct hospitalization costs during staged versus simultaneous total knee arthroplasty: Thailand National Health Security Program","volume":"61","author":"Sungkhun P","year":"2017","journal-title":"Vajira Med J"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2015.04.026"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.15105","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T04:58:55Z","timestamp":1734670735000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.15105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,5]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1111\/hae.15105"],"URL":"https:\/\/doi.org\/10.1111\/hae.15105","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,5]]},"assertion":[{"value":"2024-03-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}